Diltiazem in Achalasia
Diltiazem is NOT recommended as primary therapy for achalasia and should only be considered as a temporizing measure in patients who are not candidates for definitive treatment (pneumatic dilation, POEM, or Heller myotomy) or while awaiting these procedures.
Role in Modern Achalasia Management
Current guidelines 1, 2, 3, 4 do not include calcium channel blockers like diltiazem as standard treatment options for achalasia. The treatment paradigm has shifted entirely toward definitive interventions:
- First-line options: POEM, pneumatic dilation, or Heller myotomy with fundoplication
- Limited role for pharmacotherapy: Reserved only for patients who cannot undergo or are awaiting definitive procedures
When Diltiazem Might Be Considered
Diltiazem may have a limited role in:
- Elderly or high-risk surgical candidates who cannot tolerate pneumatic dilation, POEM, or surgery 5, 6
- Patients refusing definitive treatment while counseling continues
- Bridge therapy while awaiting scheduled procedures
- Patients who have failed botulinum toxin and are not candidates for other interventions 6
Important caveat: Even in these scenarios, botulinum toxin injection is generally preferred over oral pharmacotherapy, as it provides better symptom relief (effective in two-thirds of patients) with longer duration of action (several months) 5.
Dosing and Administration
The FDA label 7 does not list achalasia as an approved indication. When used off-label based on older literature 8:
- Typical dose: 60-90 mg orally, 30-60 minutes before meals
- Mechanism: Decreases lower esophageal sphincter pressure by reducing smooth muscle contraction 8
- Onset: Takes 30-60 minutes for adequate absorption 7
Monitoring Requirements
If diltiazem is used, monitor for:
- Cardiovascular effects: Bradycardia, AV conduction abnormalities, hypotension 7
- Hepatic function: Regular monitoring of liver enzymes, as diltiazem is extensively hepatically metabolized 7
- Renal function: Monitor in patients with renal impairment 7
- Drug interactions: Particularly with beta-blockers (risk of severe bradycardia), digoxin (increased levels), statins (increased myopathy risk), and CYP3A4 substrates 7
Critical Limitations
Diltiazem provides only modest, temporary symptom relief at best 5, 6. The evidence supporting its use is:
- Primarily from older studies (1980s-1990s)
- Not included in modern treatment algorithms
- Inferior to all definitive treatment options
- Not disease-modifying—does not address the underlying pathophysiology
Recommended Approach
Instead of diltiazem, pursue definitive treatment:
- Type I or II achalasia: POEM with PPI therapy OR Heller myotomy with fundoplication OR pneumatic dilation 9, 4
- Type III achalasia: POEM is preferred due to ability to perform longer myotomy 1, 9
- Poor surgical candidates: Botulinum toxin injection (superior to oral pharmacotherapy) 5, 6, 3
Common pitfall: Using diltiazem as long-term management delays definitive treatment and allows disease progression, potentially leading to end-stage achalasia with megaesophagus, which has worse outcomes even with definitive therapy 1.